Literature DB >> 27571355

Structure of the Epigenetic Oncogene MMSET and Inhibition by N-Alkyl Sinefungin Derivatives.

Dominic Tisi1, Elisabetta Chiarparin1, Emiliano Tamanini1, Puja Pathuri1, Joseph E Coyle1, Adam Hold1, Finn P Holding1, Nader Amin1, Agnes C L Martin1, Sharna J Rich1, Valerio Berdini1, Jeff Yon1, Paul Acklam2, Rosemary Burke2, Ludovic Drouin2, Jenny E Harmer2, Fiona Jeganathan2, Rob L M van Montfort2, Yvette Newbatt2, Marcello Tortorici2, Maura Westlake2, Amy Wood2, Swen Hoelder2, Tom D Heightman1.   

Abstract

The members of the NSD subfamily of lysine methyl transferases are compelling oncology targets due to the recent characterization of gain-of-function mutations and translocations in several hematological cancers. To date, these proteins have proven intractable to small molecule inhibition. Here, we present initial efforts to identify inhibitors of MMSET (aka NSD2 or WHSC1) using solution phase and crystal structural methods. On the basis of 2D NMR experiments comparing NSD1 and MMSET structural mobility, we designed an MMSET construct with five point mutations in the N-terminal helix of its SET domain for crystallization experiments and elucidated the structure of the mutant MMSET SET domain at 2.1 Å resolution. Both NSD1 and MMSET crystal systems proved resistant to soaking or cocrystallography with inhibitors. However, use of the close homologue SETD2 as a structural surrogate supported the design and characterization of N-alkyl sinefungin derivatives, which showed low micromolar inhibition against both SETD2 and MMSET.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27571355     DOI: 10.1021/acschembio.6b00308

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  16 in total

1.  Discovery of Potent Small-Molecule Inhibitors of MLL Methyltransferase.

Authors:  Ting-Rong Chern; Liu Liu; Elyse Petrunak; Jeanne A Stuckey; Mi Wang; Denzil Bernard; Haibin Zhou; Shirley Lee; Yali Dou; Shaomeng Wang
Journal:  ACS Med Chem Lett       Date:  2020-05-14       Impact factor: 4.345

Review 2.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

Review 3.  Seeking Convergence and Cure with New Myeloma Therapies.

Authors:  Priya Choudhry; Derek Galligan; Arun P Wiita
Journal:  Trends Cancer       Date:  2018-06-27

4.  High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.

Authors:  Nathan P Coussens; Stephen C Kales; Mark J Henderson; Olivia W Lee; Kurumi Y Horiuchi; Yuren Wang; Qing Chen; Ekaterina Kuznetsova; Jianghong Wu; Sirisha Chakka; Dorian M Cheff; Ken Chih-Chien Cheng; Paul Shinn; Kyle R Brimacombe; Min Shen; Anton Simeonov; Madhu Lal-Nag; Haiching Ma; Ajit Jadhav; Matthew D Hall
Journal:  J Biol Chem       Date:  2018-06-26       Impact factor: 5.157

Review 5.  Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.

Authors:  Faiz Anwer; Kevin Mathew Gee; Ahmad Iftikhar; Mirza Baig; Atlantis Dawn Russ; Sabina Saeed; Muhammad Abu Zar; Faryal Razzaq; Jennifer Carew; Steffan Nawrocki; Hussam Al-Kateb; Nadia Nunes Cavalcante Parr; Ali McBride; Jason Valent; Christy Samaras
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-03-25

Review 6.  Lysine methyltransferase inhibitors: where we are now.

Authors:  Alessandra Feoli; Monica Viviano; Alessandra Cipriano; Ciro Milite; Sabrina Castellano; Gianluca Sbardella
Journal:  RSC Chem Biol       Date:  2021-12-13

7.  MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.

Authors:  Zhigang Xie; Jing Yuan Chooi; Sabrina Hui Min Toh; Dongxiao Yang; Nurhidayah Binte Basri; Ying Swan Ho; Wee Joo Chng
Journal:  Leukemia       Date:  2018-11-23       Impact factor: 11.528

8.  Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.

Authors:  Renato Ferreira de Freitas; Yanli Liu; Magdalena M Szewczyk; Naimee Mehta; Fengling Li; David McLeod; Carlos Zepeda-Velázquez; David Dilworth; Ronan P Hanley; Elisa Gibson; Peter J Brown; Rima Al-Awar; Lindsey I James; Cheryl H Arrowsmith; Dalia Barsyte-Lovejoy; Jinrong Min; Masoud Vedadi; Matthieu Schapira; Abdellah Allali-Hassani
Journal:  J Med Chem       Date:  2021-02-01       Impact factor: 7.446

9.  An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.

Authors:  Alok Swaroop; Jon A Oyer; Christine M Will; Xiaoxiao Huang; Wenbo Yu; Catalina Troche; Marinka Bulic; Benjamin H Durham; Qiang Jeremy Wen; John D Crispino; Alexander D MacKerell; Richard L Bennett; Neil L Kelleher; Jonathan D Licht
Journal:  Oncogene       Date:  2018-08-31       Impact factor: 9.867

10.  Identification of a peptide inhibitor for the histone methyltransferase WHSC1.

Authors:  Michael J Morrison; P Ann Boriack-Sjodin; Kerren K Swinger; Tim J Wigle; Dipti Sadalge; Kevin W Kuntz; Margaret Porter Scott; William P Janzen; Richard Chesworth; Kenneth W Duncan; Darren M Harvey; John W Lampe; Lorna H Mitchell; Robert A Copeland
Journal:  PLoS One       Date:  2018-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.